Analyst initiates coverage of Edgewise Therapeutics with buy recommendation, stock surges
From Nasdaq: 2025-05-02 19:07:00
- Analyst Debjit Chattopadhyay initiated coverage of Edgewise Therapeutics (NASDAQ: EWTX) with a buy recommendation and a price target of $41 per share. The stock surged nearly 14% following his bullish view on the company’s promising pipeline and attractive enterprise value.
- Edgewise Therapeutics currently has an enterprise value of over $1 billion and is developing two promising drugs, EDG-7500 for hypertrophic cardiomyopathy and sevasemten for Duchenne muscular dystrophy. Clinical trial results for both treatments are expected within the next year.
- While Edgewise Therapeutics shows potential for success, investors should be cautious as the company’s fate heavily relies on the performance of its pipeline drugs. Positive results could lead to significant gains, but failure could result in losses.
- The Motley Fool Stock Advisor team did not include Edgewise Therapeutics in their list of the 10 best stocks to buy now. However, their top picks have historically generated substantial returns, with an average return of 889% compared to 162% for the S&P 500. Join Stock Advisor to access their latest recommendations.
Read more at Nasdaq: Why Edgewise Therapeutics Stock Popped This Week